We could not find any results for:
Make sure your spelling is correct or try broadening your search.
PHILADELPHIA and LONDON, Feb. 16 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc (NYSE:GSK) announced today the successful completion of the tender offer by its wholly owned subsidiary Pilgrim...
PHILADELPHIA, Feb. 15 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc (NYSE:GSK) today announced that it is extending the subsequent offering period for the cash tender offer by its wholly-owned...
PHILADELPHIA and LONDON, Feb. 7 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc (NYSE:GSK) announced today the expiration of the initial offering period of the tender offer by its wholly owned...
LONDON, Jan. 9 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc (NYSE:GSK) (GSK) announced today that Pilgrim Acquisition Corporation, a wholly owned subsidiary of GSK, is today commencing a cash...
PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS) today announced consolidated financial results for the three and nine months ended September 30, 2006. Third Quarter...
PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS) today announced that it is presenting interim clinical data from an ongoing phase 1 trial of its investigational compound...
PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS), today announced that it will report Third Quarter 2006 financial results on Thursday, November 9, 2006, before the financial...
PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS) today announced that it received the Cerep Award for Research with the greatest therapeutic potential at the 14th...
PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS) today announced that it is presenting preclinical data on its investigational compound, PPI-2458, at the 14th International...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions